Compare Organon & Co. Common Stock (OGN) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs United States Natural Gas Fund — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while United States Natural Gas Fund trades at $11.2 (market cap $503.45M). The key difference: Organon & Co. Common Stock is far larger — about 7.2× United States Natural Gas Fund's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while United States Natural Gas Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and United States Natural Gas Fund for 23 Days on average.
| OGN | UNG | |
|---|---|---|
Market Cap | $3.62B | $503.45M |
Volume | 2,892,999 | 27,352,527 |
Sector | Health | Commodities - Energy |
52-Week High | $13.81 | $16.90 |
52-Week Low | $5.70 | $9.63 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
UNG trades at $11.41, up 4.49% today, with a bullish technical signal from moving averages. The fund shows strong net income of $65.15M for 2024 despite zero revenue, supported by $593.54M in cash. Recent news highlights natural gas market volatility, with record U.S. production and geopolitical tensions influencing prices.
Outlook: Bullish technicals and solid liquidity offer upside, but reliance on natural gas price swings and zero revenue pose risks. Investors should weigh energy market stability against the fund's cash position and income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
